Business Context and Reporting Period
Company: OrthoLogic Corp. (Note: Request metadata listed "Capstone Holding Corp.", but the filing text identifies the registrant as OrthoLogic Corp.)
Filing Type: Form 10-K Annual Report
Period Ended: December 31, 1996
Business Overview: OrthoLogic develops, manufactures, and markets orthopaedic devices, primarily bone growth stimulators (Fracture Healing Products) and Continuous Passive Motion (CPM) devices (Orthopaedic Rehabilitation Products). In August 1996, the Company acquired Sutter Corporation, entering the CPM market. In March 1997, it acquired assets of Toronto Medical Corp. and Danninger Medical Technology, Inc.
Key Financial Metrics
Note: Specific revenue, profit, and cash flow figures for the fiscal year are incorporated by reference to the Annual Report to Stockholders and are not explicitly stated in the provided text.
- Accumulated Deficit: Approximately $16.9 million as of December 31, 1996.
- Profitability Status: The Company experienced significant operating losses since inception. It was first profitable in the fourth quarter of 1995, but there is no assurance of ongoing annual profitability.
- Research & Development (R&D) Expenses: $2.8 million (1994), $2.1 million (1995), and $2.2 million (1996).
- Revenue Mix (1996): Fracture Healing Products accounted for 68% of total net revenues; Orthopaedic Rehabilitation Products (CPM) accounted for 32%.
- Market Capitalization: Approximately $146.1 million (based on non-affiliate voting stock value as of February 21, 1997).
- Outstanding Shares: 25,031,846 shares of Common Stock (as of February 21, 1997).
- Debt and Liquidity: The filing text does not provide specific values for total debt, current liabilities, or cash on hand.
Material Changes vs. Prior Period
- Acquisitions: The most significant change was the acquisition of Sutter Corporation in August 1996, which diversified the product line to include CPM devices and ancillary orthopaedic products. This shifted the revenue mix from 100% Fracture Healing Products in 1995 to 68% in 1996.
- Operational Restructuring: The Company transitioned from relying on independent specialty dealers to an internal sales force of approximately 290 employees during 1996.
- Facility Issues: Post-acquisition, the Company discovered water leakage and moisture damage at its San Diego (Sutter) facility, requiring repairs and potential expense allocation with the landlord and prior owner.
- Management Changes: A new President and Chief Operating Officer hired in 1996 resigned in February 1997.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance
The Company anticipates that revenues from CPM products may be seasonal, with the fourth quarter historically being the strongest. Management expects to consolidate CPM manufacturing in Toronto and administrative functions in Phoenix, closing other facilities. The Company is seeking to expand the approved indications for its OrthoLogic 1000 device to include "delayed union" fractures (5-9 months post-injury) based on combined clinical data submitted to the FDA.
Material Risks and Contingencies
- Legal Proceedings: The Company is a defendant in multiple consolidated class-action lawsuits filed in the U.S. District Court for the District of Arizona. Plaintiffs allege securities fraud related to the Company's non-disclosure of an FDA warning letter dated May 31, 1996, regarding the promotion of the OrthoLogic 1000. The Company denies the allegations and intends to defend vigorously.
- Regulatory Risks: The FDA issued a warning letter in May 1996 regarding promotional literature and device configuration. While the Company states these issues are resolved, future regulatory approvals for new products (e.g., SpinaLogic 1000, OrthoSound) are uncertain and time-consuming.
- Third-Party Reimbursement: The Company relies on contracts with over 320 third-party payors. Consolidation among payors and cost-control measures could negatively impact margins and reimbursement levels.
- Supply Chain Dependence: The Company relies on sole-source suppliers for key components, including the microprocessor for the OrthoLogic 1000 and composite materials for OrthoFrame products.
- Product Liability: The Company maintains $12 million in aggregate liability coverage ($2 million primary + $10 million umbrella). There is no assurance claims will not exceed these limits.
Investor Verification Checklist
- Financial Statements: Verify the specific revenue, net income/loss, and cash flow figures in the Annual Report to Stockholders (incorporated by reference), as they are not detailed in the 10-K text provided.
- Litigation Status: Monitor the status of the consolidated securities class-action lawsuits regarding the FDA warning letter disclosure.
- Regulatory Approvals: Track the FDA's decision on the PMA supplement to expand the OrthoLogic 1000 indication to delayed union fractures.
- Acquisition Integration: Assess the financial impact and operational progress of integrating Sutter Corporation and the subsequent 1997 acquisitions (Toronto Medical, Danninger).
- Facility Repairs: Confirm the cost and timeline for repairing the water damage at the San Diego facility and any associated claims against the prior owner.